(Q45296274)

11 December 2017

title

Efficacy of salmeterol xinafoate powder in children with chronic persistent asthma (English)

1 reference

11 December 2017

0 references

Weinstein SF

1

1 reference

11 December 2017

Pearlman DS

2

1 reference

11 December 2017

Bronsky EA

3

1 reference

11 December 2017

Byrne A

4

1 reference

11 December 2017

Arledge T

5

1 reference

11 December 2017

Liddle R

6

1 reference

11 December 2017

Stahl E

7

1 reference

11 December 2017

language of work or name

1 reference

1 July 1998

1 reference

Annals of Allergy, Asthma & Immunology

11 December 2017

published in

1 reference

11 December 2017

volume

81

1 reference

11 December 2017

issue

1

1 reference

11 December 2017

page(s)

51-58

1 reference

A 1-week dose-ranging study of inhaled salmeterol in patients with asthma

11 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963109-2

7 January 2021

The effect of inhaled salmeterol on methacholine responsiveness in subjects with asthma up to 12 hours

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963109-2

7 January 2021

Protection against allergen-induced asthma by salmeterol

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963109-2

7 January 2021

Duration of Protection by Inhaled Salmeterol in Exercise-induced Asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963109-2

7 January 2021

Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. European Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963109-2

7 January 2021

A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963109-2

7 January 2021

Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963109-2

7 January 2021

Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963109-2

7 January 2021

A one-week dose-ranging study of inhaled salmeterol in children with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963109-2

7 January 2021

Long-term circadian effects of salmeterol in asthmatic children treated with inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963109-2

7 January 2021

Bronchodilator and bronchoprotective effects of salmeterol in young patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963109-2

7 January 2021

Effect of a single dose of inhaled salmeterol on baseline airway caliber and methacholine-induced airway obstruction in asthmatic children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963109-2

7 January 2021

Guidelines for management of asthma in adults: I--Chronic persistent asthma. Statement by the British Thoracic Society, Research Unit of the Royal College of Physicians of London, King's Fund Centre, National Asthma Campaign

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963109-2

7 January 2021

Guidelines for management of asthma in adults: II--Acute severe asthma. Statement by the British Thoracic Society, Research Unit of the Royal College of Physicians of London, King's Fund Centre, National Asthma Campaign

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963109-2

7 January 2021

Errors in inhalation technique and efficiency in inhaler use in asthmatic children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963109-2

7 January 2021

10.1016/S1081-1206(10)63109-2

Identifiers

DOI

1 reference

11 December 2017

1 reference